Roche acquiring GeneWeave

Roche (SIX:ROG; OTCQX:RHHBY) will acquire diagnostic play GeneWeave Biosciences Inc. (Los Gatos, Calif.) for $190 million up front and up to $235 million in milestones.

Roche will gain GeneWeave's vivoDx platform, which is in development to detect multi-drug resistant organisms including methicillin-resistant Staphylococcus aureus (MRSA) directly from clinical samples. vivoDx uses GeneWeave's Smarticles technology, which comprises live cell assays that measure bacterial drug resistance and susceptibility without the need for nucleic acid amplification or sample preparation. GeneWeave will be integrated into Roche Molecular Diagnostics. ...